Member Info for B2HS2L

LLP - If we were preparing to announce a JV for any product under AVCT development, might we remove reference to it from the website, until ready to announce that deal with A. N. Other, even though such a deal was agreed 'in pricipal' beforehand. - Or is that just not Kosher?

As a comparison, I had in mind two documents in two CEO safes, concerning a done deal that was not valid until signed by both parties on a set date, and at the time of signature would be the subject of an RNS by both parties?

A valid method of assuring an agreement isn't an agreement until both parties sign.

++

My last post was to state the one and only time AVA 032 has appeared in an RNS.

This was the last mention of AVA032 in an RNS on the 05.10.2023:

"AVA032 - our anti-PD-L1 Affimer® fused to the pro-inflammatory cytokine interleukin 15 (IL-15), displays encouraging efficacy when tested in multiple models of immunomodulation, stimulating a potent immune response and reversing the immunosuppressive tumour microenvironment. - source 05.10.2023 RNS"

If there were to be a change to the status of efficacy, or a further update on development, it should be announced via an RNS.

That question is better asked after we have seen:

a how much has been spent on developing / marketing YGEN products

b how much has been spent on costs of acquisition

c how much we are making now SLS are involved selling NCYT tests.

Not long to wait to find out.

Another report on the purchase of Lumira DX companies by Roche - with a further info:

03.01.24

https://www.labpulse.com/business-insights/trends-and-finance/mergers-acquisitions/article/15661157/roche-signs-350m-deal-to-buy-poc-technology-from-lumiradx?braze_int_id=64b7b1a59c412b0001d02d21&braze_ext_id=64b7b1a07ab161fb33c6ea4c

Last three paragraphs:

"The sale comes about after a year of transition for LumiraDx. The firm saw its revenues drop sharply in the first quarter of 2023 as it steered its business away from COVID-19 testing. As part of its strategic refocus and cost restructuring, the company announced it would be lay off approximately 40% of its global workforce in April.

In addition, Nasdaq issued a warning to LumiraDx last October that it would be delisted from the stock exchange after its share price fell below $1 for 30 consecutive days. The company said at the time that it planned to appeal.

According to LumiraDx, the proceeds from the sale will be used to repay outstanding amounts under a secured loan agreement; no proceeds will be distributed to the company or shareholders."

+++++

Roche benefitting from diagnostics tech company in financial distress.

Indeed - RNS 07.01.2021 - License Agreement with POINT Biopharma Inc:

"Under the terms of the agreement, Avacta will receive an upfront fee and development milestones for the first radiopharmaceutical prodrug totalling $9.5 million. Avacta will also receive milestone payments for subsequent radiopharmaceutical prodrugs of up to $8 million each, a royalty on sales of FAP-activated radiopharmaceuticals by POINT and a percentage of any sublicensing income received by POINT."

++++

Easily affordable for the Lilly, but will be much higher for future licensee's, now AVA6000 is working well.

ValJu

Posted in: NCYT

Posts: 12,265

Price: 55.00

No Opinion

RE: Agm12 Oct 2023 09:32

Voted no across the board and will continue to do so... until thge start being professional about everything :(

+++

Oh no I didn't..

Oh yes you did...

Here's to battering the DHSC in the high court in June for all Novacyt long term sufferers.

SHOW US THE MONEY!!!

Matml74 - FYI:

https://www.jpmorgan.com/content/dam/jpm/commercial-banking/insights/startups-innovation-economy/jpmorgan-chase-q1-2023-biopharma-licensing-and-venture-deals.pdf

Dated April 2023.

Haven't looked through it yet though.

At the bottom of this RNS

"James McCarthy, Acting Chief Executive Officer"

JM still acting.

So IMO JW is waiting to confer CEO status on whomever, when he feels the time is right.

You would think JW would use this opportunity to appoint JM CEO,

but as he hasn't - he must be keeping his options open.

GMCC - That first link has a publication date of Published Date: 07-Nov-2019.

My guess is that the pandemic has since blown predictions for Global Rapid Influenza Diagnostic Tests out the water.

Definitely the wrong time to release this report.

Roche enters into a definitive agreement to acquire LumiraDx's Point of Care technology combining multiple diagnostic modalities on a single platform

https://finance.yahoo.com/news/roche-enters-definitive-agreement-acquire-213000238.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAJMGahkATuIlq-4gl2teRkeyOSGvsuNXYPt1ehQh64wofDiPKSITecQVK-_tXT1Qijg71e47SAan1TG5tAqUz_nIcMJxEasGZyuQDoDtC-PnoE9jEwrx7c_Bwu06oPq3qR-baO_id0eg_AIfMXn8M_LJVQfVdobpydbpkrb_rI9y

Should we vanquish the DHSC in court next June, Novacyt could subsequently become a debt free T/O target to larger entities.

"if you've got concerns about Avacta you can always set them out in an email to Alastair Smith and see what he says."

From now on AS is going to refer to the investormeet Q/A text to reference any and all investor questions.

It should also help with many BP and journalist questions.

This is an Avacta masterstroke.

I too have had blood tests for Prostate issues.

I agree the PSA test is no longer fit for purpose, and find the info contained in this link helpful.

https://www.linkedin.com/feed/update/urn:li:activity:7102625775173935104/

Tony Cooke was CEO of Lab21, - a company in which I invested during his tenure.

I am not invested in Cambridge Clinical Laboratories or any other company mentioned, but will be taking further action as laid out in his post next year.

Apologies in advance for off topic post.

Cheers BV

I believe this is the new CBO -

https://www.linkedin.com/in/simon-bennett-a9681b/

If that's correct he has a LinkedIn presence, but he does not use LinkedIn.

Any money due to Yourgene is money Novacyt won't have to invest in Yourgene products.

I'm uncomfortable not knowing how much Novacyt have had to find to invest in Yourgene since acquisition on 08.09.2023.

In the new year, the sp will be partly dependent on the drop in Novacyt funds due to funding the Yourgene business.

I sincerely hope that we see that SLS will have markedly increased sales of Primerdesign / Genesig products since August.

https://www.lse.co.uk/ShareChat.html?ShareTicker=NCYT&share=Novacyt&thread=E1EAFF85-1E40-431F-BDAC-CE460CA056ED&reply=true

Been out all day.

Some of the posts ignore the 19th June 2023 RNS - ie

Dr Eliot Forster, Chairman of the Board of Avacta Group plc commented:

"Along with my fellow Directors I am delighted to welcome Shaun to the Board of Avacta Group. He brings a wide range of highly relevant commercial experiences from successful healthcare businesses with similar ambitions for growth that we have in Avacta. I know Shaun will positively impact our shared thinking and I'm excited to have him join the company."

Dr Alastair Smith, Chief Executive of Avacta Group plc commented:

"I am delighted that Shaun has joined the Board of Avacta Group. He brings deep and extensive commercial experience to further strengthen the senior leadership of the Group as it executes its strategy across two divisions to build a major global healthcare business working to improve people's health and well-being through innovative oncology drugs and powerful diagnostics."

Shaun Chilton, Non-Executive Director of Avacta Group, commented:

"Avacta Group is building a high value, global business that is seeking to significantly improve people's health and well-being. I am excited to leverage my own broad experience of growing healthcare businesses and working with the other members of the Board to help guide Avacta to meet its very significant potential."

I'm sure the intention was not to hire Shaun and allow him to say and do nothing.

True, we haven't heard much from him, but he will be central to turning business potential into reality, whereas most here seem to think only Alastair should be involved here.

Now this presentation to shareholders / dumbing down for journalistic reasons has been performed, and the AVA6K platform has been verified, Shaun & Co can use the new Status Quo to generate cash for phase 2 etc, I'm sure he's been given some timescales.

Sp now 132p 😁

"Given the favourable safety data from the three-weekly dosing study, a fortnightly dosing study, which is now screening patients with high FAP levels in the United States, will assist in optimising the schedule and dose for a potentially pivotal Phase 2 study in 2024."

FWIW IMO they are shortlisting fortnightly dosing study candidates.

Recall they mentioned ", the Company intends to begin a short study to explore more frequent dosing (fortnightly) of AVA6000 as a **first line treatment** in patients with soft tissue sarcoma", in the 19.09.2023 RNS

This RNS twice discusses 'high levels of FAP'

The only previous RNS that discusses 'high FAP' levels is:

28.09.2023 "Avacta's pre|CISION™ platform is a proprietary chemical modification that renders the modified chemotherapeutic drug inactive in the circulation until it enters the tumour microenvironment, where it is activated by an enzyme called FAPα. FAPα is in high abundance in most solid tumours but not in healthy tissues."

Interested to see the terminology used by the presentation team today.

Saw a program last night about removing a cancer from a 31 year old persons brain whilst he was awake, (local anaesthetic), so they could minimise damage by talking to him!

The op seemed to be successful, but he wouldn't need this if AVA6000 were available to him.

A very large sum of money to be saved by health authorities / Insurers here, and a much less dangerous way of beating cancer.